Oxford Asset Management’s Medicines Co MDCO Stock Holding History

Oxford Asset Management’s Portfolio MDCO Stock Details MDCO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-271,046	Closed	-$23M	–	1720
2019 Q4	$23M	Buy	+271,046	New	+$18.1M	0.64%	16
2018 Q4	–	Sell	-10,149	Closed	-$296K	–	2251
2018 Q3	$296K	Buy	+10,149	New	+$382K	0.01%	1498
2015 Q4	–	Sell	-63,159	Closed	-$2.4M	–	992
2015 Q3	$2.4M	Buy	+63,159	New	+$2.22M	0.08%	265
2015 Q1	–	Sell	-361,991	Closed	-$9.97M	–	794
2014 Q4	$9.97M	Buy	361,991 +47,030	+15%	+$1.17M	0.22%	82
2014 Q3	$7.16M	Buy	+314,961	New	+$8M	0.16%	127
2013 Q4	–	Sell	-47,556	Closed	-$1.59M	–	840
2013 Q3	$1.59M	Sell	47,556 -7,224	-13%	-$230K	0.04%	516
2013 Q2	$1.69M	Buy	+54,780	New	+$1.83M	0.05%	486

Other funds holding MDCO

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Oxford Asset Management's MDCO Position: Q1 2020 in Review

Oxford Asset Management sold out of Medicines Co (MDCO) in Q1 2020, closing a stake of 271,046 shares — an estimated $23M sold.

Oxford Asset Management first reported a position in MDCO in Q2 2013 and held it in 7 quarters. The position peaked at $23M in Q4 2019. 1 fund tracked by Wall St. Rank holds MDCO as of Q1 2020.

Oxford Asset Management reported no remaining Medicines Co position as of Q1 2020 after selling out during the quarter.
Oxford Asset Management sold 271,046 Medicines Co shares in Q1 2020, an estimated $23M.
Oxford Asset Management first reported a position in Medicines Co in Q2 2013 and held it in 7 quarters.
Oxford Asset Management's Medicines Co position peaked at $23M in Q4 2019.
1 fund tracked by Wall St. Rank held Medicines Co as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.